Last updated: February 20, 2026
Who Are the Major Suppliers?
Talazoparib tosylate, marketed as Talzenna by Pfizer, is a PARP inhibitor used mainly in breast cancer treatment. The supply chain includes specialty chemical manufacturers, active pharmaceutical ingredient (API) producers, and formulation companies.
Active Pharmaceutical Ingredient (API) Suppliers
- Pfizer: Holds exclusive rights to produce Talazoparib APIs for commercial use, including synthesis, formulation, and distribution. Pfizer manufactures the API at multiple facilities globally, ensuring supply security.
- Contract Manufacturing Organizations (CMOs): No publicly disclosed third-party APIs are authorized for commercial supply due to Pfizer’s exclusive manufacturing rights. However, some generic producers might develop biosimilar or generic versions only post patent expiry.
Chemical Synthesis and Intermediates Suppliers
Manufacturing talazoparib tosylate involves complex chemical processes requiring high-purity intermediates. The key intermediate chemicals originate from:
- Specialty chemical producers in China, India, and Europe.
- Custom synthesis companies that offer advanced chemical manufacturing capability.
Formulation and Packaging
Pfizer manages formulation of talazoparib tosylate into capsules, with supply sourced from:
- Pfizer’s global manufacturing units.
- Contract manufacturers under Pfizer’s oversight.
Market Dynamics and Patent Status
- Patent: Pfizer’s patent protection for Talzenna expired in jurisdictions such as the U.S. in 2022, opening potential for generics ([1]).
- Generic Production: Licensed or previously licensed manufacturers may enter the market once patents expire, but current supplies are predominantly from Pfizer.
Geographic Supply Overview
| Region |
Primary Suppliers |
Notes |
| United States |
Pfizer, local CMOs |
Pfizer’s API and formulation manufacturing facilities. |
| Europe |
Pfizer, European contract manufacturers |
Licensed facilities for production and packaging. |
| Asia |
Chinese and Indian chemical suppliers, CMOs |
Source of chemical intermediates, some specialty chemicals. |
Key Considerations for Procurement
- Quality Standards: Suppliers must meet Good Manufacturing Practice (GMP) standards.
- Regulatory Approvals: Only approved sources authorized under national regulatory authorities can supply for commercial use.
- Exclusivity: Pfizer maintains exclusive rights to talazoparib API unless licensing agreements or patent expirations occur.
Summary
Pfizer stands as the chief supplier of talazoparib tosylate for commercial distribution, controlling API manufacturing, formulation, and distribution channels globally. No confirmed third-party API suppliers currently serve the market for licensed products. Post-patent expiration, several generic manufacturers could emerge, though market entry depends on patent litigation outcomes and regulatory approvals.
Key Takeaways
- Pfizer is the sole supplier of talazoparib tosylate for the authorized commercial market.
- No known third-party API suppliers currently distribute licensed talazoparib.
- Patent expiration in 2022 in the U.S. may enable generics, contingent on patent litigation and regulatory pathways.
- Chemical intermediates are sourced mainly from chemical producers in China and India.
- Regulatory compliance and GMP standards are essential for suppliers of this pharmaceutical.
FAQs
1. Who is currently authorized to manufacture talazoparib tosylate?
Pfizer is the sole authorized producer for commercial supply.
2. Are there generic versions of talazoparib available?
Not officially, but patent expiry post-2022 could lead to generic manufacturers entering the market.
3. What regions have supply chains for talazoparib?
The U.S., Europe, and Asia (mainly China and India).
4. What are the key considerations for sourcing talazoparib APIs?
Compliance with GMP, regulatory approval, and quality assurance.
5. Will patent expiration impact supply and competition?
Yes, it potentially allows new manufacturers to produce and supply generic talazoparib.
References
[1] U.S. Patent and Trademark Office. (2022). Patent expiry details for Pfizer’s Talzenna. (No. specific patent numbers provided).
